Q-omics provides the consensus-scored ZP2 profile across patient tissues and cancer cell-line models. ZP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ZP2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZP2 RNA expression shows 7,341 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KIRC, and TGCT as cancer lineages where ZP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZP2 survival associations across molecular data types. ZP2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZP2 RNA expression–survival associations across cancer types. High ZP2 expression shows unfavorable associations in DLBC, SKCM, MESO, LUSC and LIHC, but favorable associations in READ. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify DLBC as the clearest survival context for ZP2 RNA expression.
This table summarizes ZP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZP2 shows lower tumor expression in KIRC, THCA, KIRP, LUSC, HNSC and LUAD. The KIRC box plot shows higher ZP2 RNA expression in normal versus tumor tissue (log2 FC = −0.215, t-test p < 0.001).
This table shows molecular features associated with ZP2 in patient tissues and cancer cell lines. In patient samples, ZP2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
